nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ABCC2—Carboplatin—brain cancer	0.225	0.266	CbGbCtD
Canagliflozin—ABCC2—Etoposide—brain cancer	0.189	0.224	CbGbCtD
Canagliflozin—CYP3A4—Temozolomide—brain cancer	0.18	0.213	CbGbCtD
Canagliflozin—CYP3A4—Lomustine—brain cancer	0.153	0.181	CbGbCtD
Canagliflozin—ABCB1—Etoposide—brain cancer	0.0616	0.0729	CbGbCtD
Canagliflozin—CYP3A4—Etoposide—brain cancer	0.0369	0.0437	CbGbCtD
Canagliflozin—Dapagliflozin—CYP2C9—brain cancer	0.0165	1	CrCbGaD
Canagliflozin—Nocturia—Procarbazine—brain cancer	0.00344	0.0319	CcSEcCtD
Canagliflozin—Photosensitivity—Procarbazine—brain cancer	0.00264	0.0245	CcSEcCtD
Canagliflozin—Blood urea increased—Hydroxyurea—brain cancer	0.00233	0.0216	CcSEcCtD
Canagliflozin—Rash maculo-papular—Hydroxyurea—brain cancer	0.00224	0.0208	CcSEcCtD
Canagliflozin—SLC5A2—Orphan transporters—S100A10—brain cancer	0.00207	0.0664	CbGpPWpGaD
Canagliflozin—SLC5A1—Orphan transporters—S100A10—brain cancer	0.00207	0.0664	CbGpPWpGaD
Canagliflozin—Infection—Carboplatin—brain cancer	0.00203	0.0189	CcSEcCtD
Canagliflozin—Pancreatitis—Procarbazine—brain cancer	0.00196	0.0182	CcSEcCtD
Canagliflozin—Renal failure acute—Hydroxyurea—brain cancer	0.00194	0.018	CcSEcCtD
Canagliflozin—Pollakiuria—Procarbazine—brain cancer	0.00185	0.0171	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Procarbazine—brain cancer	0.00183	0.0169	CcSEcCtD
Canagliflozin—Vaginal infection—Temozolomide—brain cancer	0.00182	0.0169	CcSEcCtD
Canagliflozin—Infection—Lomustine—brain cancer	0.00178	0.0165	CcSEcCtD
Canagliflozin—Blood creatinine increased—Hydroxyurea—brain cancer	0.00168	0.0156	CcSEcCtD
Canagliflozin—Diabetes mellitus—Carmustine—brain cancer	0.00166	0.0154	CcSEcCtD
Canagliflozin—Breast disorder—Hydroxyurea—brain cancer	0.00162	0.015	CcSEcCtD
Canagliflozin—UGT2B4—Farnesoid X Receptor  Pathway—IRS2—brain cancer	0.00155	0.0497	CbGpPWpGaD
Canagliflozin—Pancreatitis—Hydroxyurea—brain cancer	0.00152	0.0141	CcSEcCtD
Canagliflozin—Thirst—Temozolomide—brain cancer	0.00147	0.0136	CcSEcCtD
Canagliflozin—Rash maculo-papular—Etoposide—brain cancer	0.0014	0.013	CcSEcCtD
Canagliflozin—Dehydration—Temozolomide—brain cancer	0.0013	0.0121	CcSEcCtD
Canagliflozin—Breast disorder—Temozolomide—brain cancer	0.00126	0.0117	CcSEcCtD
Canagliflozin—UGT1A9—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.00126	0.0404	CbGpPWpGaD
Canagliflozin—Syncope—Procarbazine—brain cancer	0.00125	0.0116	CcSEcCtD
Canagliflozin—ABCC2—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.00123	0.0394	CbGpPWpGaD
Canagliflozin—Loss of consciousness—Procarbazine—brain cancer	0.00123	0.0114	CcSEcCtD
Canagliflozin—Convulsion—Procarbazine—brain cancer	0.00121	0.0112	CcSEcCtD
Canagliflozin—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.00117	0.0375	CbGpPWpGaD
Canagliflozin—Dry mouth—Procarbazine—brain cancer	0.00116	0.0108	CcSEcCtD
Canagliflozin—Infection—Procarbazine—brain cancer	0.00113	0.0105	CcSEcCtD
Canagliflozin—Angiopathy—Hydroxyurea—brain cancer	0.00112	0.0104	CcSEcCtD
Canagliflozin—Shock—Procarbazine—brain cancer	0.00112	0.0104	CcSEcCtD
Canagliflozin—Pollakiuria—Temozolomide—brain cancer	0.00112	0.0104	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Temozolomide—brain cancer	0.0011	0.0102	CcSEcCtD
Canagliflozin—Urinary tract infection—Carmustine—brain cancer	0.00108	0.0101	CcSEcCtD
Canagliflozin—Erythema—Hydroxyurea—brain cancer	0.00108	0.01	CcSEcCtD
Canagliflozin—Nausea—Lomustine—brain cancer	0.00106	0.00988	CcSEcCtD
Canagliflozin—Hypotension—Procarbazine—brain cancer	0.00106	0.00986	CcSEcCtD
Canagliflozin—Urinary tract infection—Temozolomide—brain cancer	0.00105	0.00973	CcSEcCtD
Canagliflozin—Fatigue—Procarbazine—brain cancer	0.000981	0.0091	CcSEcCtD
Canagliflozin—Constipation—Procarbazine—brain cancer	0.000973	0.00903	CcSEcCtD
Canagliflozin—Urinary tract disorder—Temozolomide—brain cancer	0.000956	0.00887	CcSEcCtD
Canagliflozin—Urethral disorder—Temozolomide—brain cancer	0.000949	0.00881	CcSEcCtD
Canagliflozin—Convulsion—Hydroxyurea—brain cancer	0.000935	0.00867	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Procarbazine—brain cancer	0.00093	0.00863	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.000912	0.00846	CcSEcCtD
Canagliflozin—Urticaria—Procarbazine—brain cancer	0.000904	0.00839	CcSEcCtD
Canagliflozin—Abdominal pain—Procarbazine—brain cancer	0.000899	0.00834	CcSEcCtD
Canagliflozin—UGT2B4—Biological oxidations—CYP2C9—brain cancer	0.000886	0.0284	CbGpPWpGaD
Canagliflozin—Angiopathy—Temozolomide—brain cancer	0.000878	0.00815	CcSEcCtD
Canagliflozin—Infection—Hydroxyurea—brain cancer	0.000875	0.00812	CcSEcCtD
Canagliflozin—UGT2B4—Metapathway biotransformation—CYP2C9—brain cancer	0.000873	0.028	CbGpPWpGaD
Canagliflozin—Malnutrition—Carmustine—brain cancer	0.000872	0.00809	CcSEcCtD
Canagliflozin—Erythema—Carmustine—brain cancer	0.000872	0.00809	CcSEcCtD
Canagliflozin—Nervous system disorder—Hydroxyurea—brain cancer	0.000863	0.00801	CcSEcCtD
Canagliflozin—Skin disorder—Hydroxyurea—brain cancer	0.000855	0.00794	CcSEcCtD
Canagliflozin—Erythema—Temozolomide—brain cancer	0.000843	0.00782	CcSEcCtD
Canagliflozin—Malnutrition—Temozolomide—brain cancer	0.000843	0.00782	CcSEcCtD
Canagliflozin—Hypersensitivity—Procarbazine—brain cancer	0.000838	0.00778	CcSEcCtD
Canagliflozin—Asthenia—Procarbazine—brain cancer	0.000816	0.00757	CcSEcCtD
Canagliflozin—Pruritus—Procarbazine—brain cancer	0.000805	0.00747	CcSEcCtD
Canagliflozin—Angioedema—Temozolomide—brain cancer	0.00077	0.00715	CcSEcCtD
Canagliflozin—Urinary tract disorder—Etoposide—brain cancer	0.000765	0.0071	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.00076	0.00705	CcSEcCtD
Canagliflozin—Urethral disorder—Etoposide—brain cancer	0.000759	0.00705	CcSEcCtD
Canagliflozin—Fatigue—Hydroxyurea—brain cancer	0.000759	0.00704	CcSEcCtD
Canagliflozin—Convulsion—Carmustine—brain cancer	0.000756	0.00701	CcSEcCtD
Canagliflozin—Constipation—Hydroxyurea—brain cancer	0.000753	0.00699	CcSEcCtD
Canagliflozin—Dizziness—Procarbazine—brain cancer	0.000752	0.00698	CcSEcCtD
Canagliflozin—Convulsion—Temozolomide—brain cancer	0.00073	0.00678	CcSEcCtD
Canagliflozin—Rash—Procarbazine—brain cancer	0.000717	0.00666	CcSEcCtD
Canagliflozin—Dermatitis—Procarbazine—brain cancer	0.000717	0.00665	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000712	0.00661	CcSEcCtD
Canagliflozin—Infection—Carmustine—brain cancer	0.000707	0.00656	CcSEcCtD
Canagliflozin—Angiopathy—Etoposide—brain cancer	0.000703	0.00652	CcSEcCtD
Canagliflozin—Dry mouth—Temozolomide—brain cancer	0.000702	0.00651	CcSEcCtD
Canagliflozin—Infection—Temozolomide—brain cancer	0.000683	0.00634	CcSEcCtD
Canagliflozin—Nausea—Procarbazine—brain cancer	0.000676	0.00627	CcSEcCtD
Canagliflozin—Nervous system disorder—Temozolomide—brain cancer	0.000674	0.00626	CcSEcCtD
Canagliflozin—Skin disorder—Temozolomide—brain cancer	0.000668	0.0062	CcSEcCtD
Canagliflozin—Hypotension—Carmustine—brain cancer	0.000665	0.00617	CcSEcCtD
Canagliflozin—Hypersensitivity—Hydroxyurea—brain cancer	0.000649	0.00602	CcSEcCtD
Canagliflozin—UGT1A9—Irinotecan Pathway—APC—brain cancer	0.000646	0.0207	CbGpPWpGaD
Canagliflozin—Asthenia—Hydroxyurea—brain cancer	0.000632	0.00586	CcSEcCtD
Canagliflozin—ABCC2—Irinotecan Pathway—APC—brain cancer	0.000631	0.0202	CbGpPWpGaD
Canagliflozin—Gastrointestinal disorder—Carmustine—brain cancer	0.000614	0.0057	CcSEcCtD
Canagliflozin—Constipation—Carmustine—brain cancer	0.000609	0.00565	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Temozolomide—brain cancer	0.000594	0.00551	CcSEcCtD
Canagliflozin—Fatigue—Temozolomide—brain cancer	0.000593	0.0055	CcSEcCtD
Canagliflozin—Loss of consciousness—Etoposide—brain cancer	0.000593	0.0055	CcSEcCtD
Canagliflozin—Constipation—Temozolomide—brain cancer	0.000588	0.00546	CcSEcCtD
Canagliflozin—Convulsion—Etoposide—brain cancer	0.000584	0.00542	CcSEcCtD
Canagliflozin—Dizziness—Hydroxyurea—brain cancer	0.000582	0.0054	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Carmustine—brain cancer	0.000582	0.0054	CcSEcCtD
Canagliflozin—ABCB1—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.000577	0.0185	CbGpPWpGaD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.00057	0.00529	CcSEcCtD
Canagliflozin—Abdominal pain—Carmustine—brain cancer	0.000563	0.00522	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Temozolomide—brain cancer	0.000562	0.00522	CcSEcCtD
Canagliflozin—Rash—Hydroxyurea—brain cancer	0.000555	0.00515	CcSEcCtD
Canagliflozin—Dermatitis—Hydroxyurea—brain cancer	0.000555	0.00515	CcSEcCtD
Canagliflozin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.00055	0.0177	CbGpPWpGaD
Canagliflozin—Infection—Etoposide—brain cancer	0.000547	0.00507	CcSEcCtD
Canagliflozin—Urticaria—Temozolomide—brain cancer	0.000546	0.00507	CcSEcCtD
Canagliflozin—Abdominal pain—Temozolomide—brain cancer	0.000544	0.00505	CcSEcCtD
Canagliflozin—Skin disorder—Etoposide—brain cancer	0.000535	0.00496	CcSEcCtD
Canagliflozin—Hypersensitivity—Carmustine—brain cancer	0.000524	0.00487	CcSEcCtD
Canagliflozin—Nausea—Hydroxyurea—brain cancer	0.000523	0.00485	CcSEcCtD
Canagliflozin—CYP3A4—Xenobiotics—CYP2C9—brain cancer	0.000518	0.0166	CbGpPWpGaD
Canagliflozin—Hypotension—Etoposide—brain cancer	0.000514	0.00477	CcSEcCtD
Canagliflozin—Asthenia—Carmustine—brain cancer	0.000511	0.00474	CcSEcCtD
Canagliflozin—Hypersensitivity—Temozolomide—brain cancer	0.000507	0.0047	CcSEcCtD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—S100A10—brain cancer	0.000505	0.0162	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—S100A10—brain cancer	0.000505	0.0162	CbGpPWpGaD
Canagliflozin—CYP3A4—Tamoxifen metabolism—CYP2C9—brain cancer	0.000498	0.016	CbGpPWpGaD
Canagliflozin—Asthenia—Temozolomide—brain cancer	0.000493	0.00458	CcSEcCtD
Canagliflozin—Pruritus—Temozolomide—brain cancer	0.000487	0.00452	CcSEcCtD
Canagliflozin—SLC5A1—Carbohydrate metabolism—ENO2—brain cancer	0.000478	0.0153	CbGpPWpGaD
Canagliflozin—SLC5A2—Carbohydrate metabolism—ENO2—brain cancer	0.000478	0.0153	CbGpPWpGaD
Canagliflozin—Gastrointestinal disorder—Etoposide—brain cancer	0.000475	0.00441	CcSEcCtD
Canagliflozin—Fatigue—Etoposide—brain cancer	0.000474	0.0044	CcSEcCtD
Canagliflozin—Dizziness—Carmustine—brain cancer	0.000471	0.00437	CcSEcCtD
Canagliflozin—Constipation—Etoposide—brain cancer	0.000471	0.00437	CcSEcCtD
Canagliflozin—Dizziness—Temozolomide—brain cancer	0.000455	0.00422	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Etoposide—brain cancer	0.00045	0.00418	CcSEcCtD
Canagliflozin—Rash—Carmustine—brain cancer	0.000449	0.00416	CcSEcCtD
Canagliflozin—Dermatitis—Carmustine—brain cancer	0.000448	0.00416	CcSEcCtD
Canagliflozin—Urticaria—Etoposide—brain cancer	0.000437	0.00406	CcSEcCtD
Canagliflozin—Abdominal pain—Etoposide—brain cancer	0.000435	0.00404	CcSEcCtD
Canagliflozin—Rash—Temozolomide—brain cancer	0.000434	0.00402	CcSEcCtD
Canagliflozin—Dermatitis—Temozolomide—brain cancer	0.000433	0.00402	CcSEcCtD
Canagliflozin—Nausea—Carmustine—brain cancer	0.000423	0.00392	CcSEcCtD
Canagliflozin—UGT1A9—PPAR Alpha Pathway—CDK4—brain cancer	0.000419	0.0134	CbGpPWpGaD
Canagliflozin—Nausea—Temozolomide—brain cancer	0.000409	0.00379	CcSEcCtD
Canagliflozin—Hypersensitivity—Etoposide—brain cancer	0.000405	0.00376	CcSEcCtD
Canagliflozin—Asthenia—Etoposide—brain cancer	0.000395	0.00366	CcSEcCtD
Canagliflozin—Pruritus—Etoposide—brain cancer	0.000389	0.00361	CcSEcCtD
Canagliflozin—Dizziness—Etoposide—brain cancer	0.000364	0.00338	CcSEcCtD
Canagliflozin—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.000356	0.0114	CbGpPWpGaD
Canagliflozin—Rash—Etoposide—brain cancer	0.000347	0.00322	CcSEcCtD
Canagliflozin—SLC5A1—Disease—DTX2—brain cancer	0.000347	0.0111	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—DTX2—brain cancer	0.000347	0.0111	CbGpPWpGaD
Canagliflozin—Dermatitis—Etoposide—brain cancer	0.000347	0.00322	CcSEcCtD
Canagliflozin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.000339	0.0109	CbGpPWpGaD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—HES1—brain cancer	0.000338	0.0109	CbGpPWpGaD
Canagliflozin—UGT1A9—Biological oxidations—CYP2C9—brain cancer	0.000328	0.0105	CbGpPWpGaD
Canagliflozin—Nausea—Etoposide—brain cancer	0.000327	0.00303	CcSEcCtD
Canagliflozin—UGT1A9—Metapathway biotransformation—CYP2C9—brain cancer	0.000323	0.0104	CbGpPWpGaD
Canagliflozin—UGT1A9—PPAR Alpha Pathway—CCND1—brain cancer	0.00027	0.00867	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—HES5—brain cancer	0.000254	0.00817	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—HES5—brain cancer	0.000254	0.00817	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—TRPC6—brain cancer	0.000233	0.00749	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—TRPC6—brain cancer	0.000233	0.00749	CbGpPWpGaD
Canagliflozin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—SKP2—brain cancer	0.000225	0.00722	CbGpPWpGaD
Canagliflozin—UGT1A9—PPAR Alpha Pathway—MYC—brain cancer	0.000217	0.00696	CbGpPWpGaD
Canagliflozin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000215	0.0069	CbGpPWpGaD
Canagliflozin—CYP3A4—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000212	0.00681	CbGpPWpGaD
Canagliflozin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDK6—brain cancer	0.0002	0.00643	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—CYP2C9—brain cancer	0.000196	0.0063	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—CYP2C9—brain cancer	0.000196	0.0063	CbGpPWpGaD
Canagliflozin—CYP3A4—Irinotecan Pathway—APC—brain cancer	0.000183	0.00586	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—MPL—brain cancer	0.000177	0.00567	CbGpPWpGaD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL2—brain cancer	0.000176	0.00564	CbGpPWpGaD
Canagliflozin—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000174	0.0056	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—IDH1—brain cancer	0.000171	0.0055	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—IDH1—brain cancer	0.000171	0.0055	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—BSG—brain cancer	0.000167	0.00535	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—BSG—brain cancer	0.000167	0.00535	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—SOD2—brain cancer	0.000163	0.00522	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—HEY1—brain cancer	0.000162	0.00521	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—HEY1—brain cancer	0.000162	0.00521	CbGpPWpGaD
Canagliflozin—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—brain cancer	0.000162	0.0052	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—DLL1—brain cancer	0.000159	0.00511	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—DLL1—brain cancer	0.000159	0.00511	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—CYP2C9—brain cancer	0.000151	0.00486	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—IDH1—brain cancer	0.000143	0.0046	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—IDH1—brain cancer	0.000143	0.0046	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—S100A10—brain cancer	0.000141	0.00452	CbGpPWpGaD
Canagliflozin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—brain cancer	0.00014	0.00451	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—ENO2—brain cancer	0.000135	0.00434	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—ENO2—brain cancer	0.000135	0.00434	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—SHH—brain cancer	0.000135	0.00434	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—SHH—brain cancer	0.000135	0.00434	CbGpPWpGaD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—brain cancer	0.000134	0.00431	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—SOD2—brain cancer	0.000132	0.00425	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—BSG—brain cancer	0.000129	0.00413	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	0.000126	0.00404	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—ENO2—brain cancer	0.000113	0.00364	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—ENO2—brain cancer	0.000113	0.00364	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—IDH1—brain cancer	0.000111	0.00355	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—SOD2—brain cancer	0.000105	0.00337	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—VAV1—brain cancer	9.78e-05	0.00314	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—VAV1—brain cancer	9.78e-05	0.00314	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—PDGFRA—brain cancer	9.58e-05	0.00307	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—RELA—brain cancer	9.4e-05	0.00302	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—CYP2C9—brain cancer	9.26e-05	0.00297	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—IDH1—brain cancer	9.2e-05	0.00295	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—CYP2C9—brain cancer	9.14e-05	0.00293	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—MPL—brain cancer	9.11e-05	0.00292	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—ENO2—brain cancer	8.75e-05	0.00281	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—S100A10—brain cancer	8.73e-05	0.0028	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—HES1—brain cancer	8.41e-05	0.0027	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—HES1—brain cancer	8.41e-05	0.0027	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PDGFRA—brain cancer	8.01e-05	0.00257	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PDGFRA—brain cancer	8.01e-05	0.00257	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—brain cancer	7.99e-05	0.00256	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—TRPC6—brain cancer	7.83e-05	0.00251	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—RELA—brain cancer	7.65e-05	0.00246	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—brain cancer	7.58e-05	0.00243	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—S100A10—brain cancer	7.56e-05	0.00243	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—IRS2—brain cancer	7.03e-05	0.00226	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—IRS2—brain cancer	7.03e-05	0.00226	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—IL2—brain cancer	6.89e-05	0.00221	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—S100A10—brain cancer	6.62e-05	0.00213	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	6.59e-05	0.00211	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—TRPC6—brain cancer	6.51e-05	0.00209	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—brain cancer	6.39e-05	0.00205	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—APC—brain cancer	6.21e-05	0.00199	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—APC—brain cancer	6.21e-05	0.00199	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—BSG—brain cancer	6.15e-05	0.00198	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—RELA—brain cancer	6.08e-05	0.00195	CbGpPWpGaD
Canagliflozin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—brain cancer	5.99e-05	0.00192	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—VAV1—brain cancer	5.86e-05	0.00188	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYP2C9—brain cancer	5.6e-05	0.0018	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—brain cancer	5.25e-05	0.00169	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL2—brain cancer	5.23e-05	0.00168	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PIK3CG—brain cancer	5.2e-05	0.00167	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PIK3CG—brain cancer	5.2e-05	0.00167	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—SIRT1—brain cancer	5.15e-05	0.00165	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—brain cancer	5.13e-05	0.00165	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—brain cancer	5.09e-05	0.00163	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—VEGFA—brain cancer	5.02e-05	0.00161	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—ERBB2—brain cancer	4.82e-05	0.00155	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—ERBB2—brain cancer	4.82e-05	0.00155	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—IDH1—brain cancer	4.82e-05	0.00155	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—brain cancer	4.78e-05	0.00153	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—BSG—brain cancer	4.77e-05	0.00153	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—brain cancer	4.73e-05	0.00152	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—brain cancer	4.5e-05	0.00145	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—VEGFA—brain cancer	4.44e-05	0.00143	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—TP53—brain cancer	4.42e-05	0.00142	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CTNNB1—brain cancer	4.22e-05	0.00135	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CTNNB1—brain cancer	4.22e-05	0.00135	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—IDH1—brain cancer	4.1e-05	0.00132	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TRPC6—brain cancer	4.03e-05	0.00129	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PIK3CG—brain cancer	4.02e-05	0.00129	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—brain cancer	3.89e-05	0.00125	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PIK3CG—brain cancer	3.72e-05	0.00119	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—STAT3—brain cancer	3.68e-05	0.00118	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—STAT3—brain cancer	3.68e-05	0.00118	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—APC—brain cancer	3.67e-05	0.00118	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—TRPC6—brain cancer	3.49e-05	0.00112	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—MYC—brain cancer	3.42e-05	0.0011	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—MYC—brain cancer	3.42e-05	0.0011	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—EGFR—brain cancer	3.34e-05	0.00107	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—EGFR—brain cancer	3.34e-05	0.00107	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	3.34e-05	0.00107	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ENO2—brain cancer	3.24e-05	0.00104	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—TRPC6—brain cancer	3.06e-05	0.000982	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—VAV1—brain cancer	3.02e-05	0.00097	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP2C9—brain cancer	2.93e-05	0.000942	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—brain cancer	2.85e-05	0.000914	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—IL2—brain cancer	2.62e-05	0.000841	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP2C9—brain cancer	2.57e-05	0.000825	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	2.51e-05	0.000807	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—BSG—brain cancer	2.5e-05	0.000801	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	2.49e-05	0.000799	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—VEGFA—brain cancer	2.23e-05	0.000715	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	2.19e-05	0.000704	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—BSG—brain cancer	2.19e-05	0.000702	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—IDH1—brain cancer	2.15e-05	0.000689	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	2.02e-05	0.000647	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	1.97e-05	0.000633	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CG—brain cancer	1.92e-05	0.000616	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—IDH1—brain cancer	1.88e-05	0.000603	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	1.75e-05	0.000561	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ENO2—brain cancer	1.7e-05	0.000544	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	1.66e-05	0.000532	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP2C9—brain cancer	1.58e-05	0.000508	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CG—brain cancer	1.49e-05	0.000477	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ENO2—brain cancer	1.49e-05	0.000477	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IL2—brain cancer	1.35e-05	0.000433	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—BSG—brain cancer	1.35e-05	0.000432	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—IDH1—brain cancer	1.16e-05	0.000372	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—VEGFA—brain cancer	1.15e-05	0.000368	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ENO2—brain cancer	9.16e-06	0.000294	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TP53—brain cancer	8.67e-06	0.000278	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CG—brain cancer	7.78e-06	0.00025	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CG—brain cancer	6.82e-06	0.000219	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CG—brain cancer	4.2e-06	0.000135	CbGpPWpGaD
